Updated:
Virax Biolabs Group Ltd
Virax Biolabs Group Ltd is a diagnostics and immunology company listed on the AIM market of the London Stock Exchange. The firm focuses on T-cell testing...
Virax Biolabs Group Ltd
Virax Biolabs Group Ltd is a diagnostics and immunology company listed on the AIM market of the London Stock Exchange. The firm focuses on T-cell testing technologies for viral infections, including COVID-19, hepatitis B, and cytomegalovirus. Its primary product candidate is the Virax ImmPrint platform, designed to measure cellular immune responses through a blood test. The company was incorporated in the United Kingdom and has disclosed limited information about its management structure or founding timeline. The company's strategy centers on commercializing diagnostic tools for infectious disease monitoring. Virax Biolabs has reported development-stage work on its T-cell assay platform but has not disclosed substantial revenue generation or clinical trial results in peer-reviewed journals. The firm's asset-class exposure is limited to its own equity and development-stage investments. No named portfolio companies, co-investors, or external fund commitments have been confirmed. As of 2025, Virax Biolabs Group Ltd remains a small-cap public company with no publicly available data on team size, assets under management, or institutional investor base. The firm's public filings indicate it has raised capital through equity placements on AIM. No adjacent vehicles, such as foundations or operating businesses, have been disclosed in public records. Virax Biolabs' structural differentiator is its focus on T-cell diagnostics within a small-cap public equity structure, which offers liquidity through the AIM exchange. The firm has not provided transparency on its corporate governance or succession planning. Its limited public profile makes it distinct from larger family offices or asset managers that operate with broader mandates.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
Europe
Country
—
City
—
Corporate office
—
Frequently asked questions
Who runs investment decisions at Virax Biolabs Group Ltd?
Virax Biolabs Group Ltd is a public company, so investment decisions related to the firm's equity are made by its board of directors and executive management team. Per public filings, the company's CEO Dr. Jonathan Barrett was appointed in May 2025. The firm's small-cap structure means that strategic decisions regarding capital allocation are typically determined by the board in consultation with shareholders. No dedicated asset management or investment committee has been disclosed.
What is Virax Biolabs' core technology platform?
The company's lead product is the Virax ImmPrint platform, a T-cell testing system designed to measure cellular immune responses to viral infections. This test aims to differentiate between various viral exposures and provide information on immune memory, including for COVID-19, hepatitis B, and other viruses. The technology is still in development and has not been commercialized or validated in large-scale clinical settings, according to public records.
Is Virax Biolabs Group Ltd structured as a family office or an investment firm?
Virax Biolabs Group Ltd is not a family office or traditional asset manager. It is a publicly traded biotechnology company listed on the London Stock Exchange's AIM market. The firm operates as a development-stage diagnostics business, not as an investment vehicle. Its focus is on product development and commercialization, not on managing third-party capital or making external investments.
What investment stages does Virax Biolabs target, if any?
As a diagnostics developer, Virax Biolabs does not target investment stages in the traditional sense. Its capital allocation is directed toward product development, regulatory approvals, and potential market entry for its diagnostic platforms. The firm's public filings indicate it has raised equity capital through placements on AIM, suggesting a focus on growth-stage financing for its own operations rather than investing in external companies.
Where does the underlying wealth originate for Virax Biolabs?
Virax Biolabs Group Ltd is a publicly traded company, so its capital comes from equity investors on the London Stock Exchange's AIM market. The firm has not disclosed any specific family, institutional, or high-net-worth individual as a primary source of wealth. Its fundraising history involves public equity placements, with shareholders including retail and institutional investors who buy and sell shares on the open market.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: